Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · IEX Real-Time Price · USD
2.300
0.00 (0.00%)
At close: Mar 27, 2024, 12:00 AM
2.340
+0.040 (1.74%)
Pre-market: Mar 28, 2024, 8:55 AM EDT

Inhibikase Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018
Revenue
0.260.123.10.71.124.04
Revenue Growth (YoY)
111.03%-96.02%343.92%-37.79%-72.22%-
Gross Profit
0.260.123.10.71.124.04
Selling, General & Admin
6.736.226.512.624.272.52
Research & Development
13.6212.0311.360.892.553.65
Operating Expenses
20.3518.2517.873.526.826.16
Operating Income
-20.09-18.13-14.77-2.82-5.7-2.12
Interest Expense / Income
000.020.030.020.03
Other Expense / Income
-1.06-0.07----
Pretax Income
-19.03-18.05-14.79-2.85-5.72-2.15
Net Income
-19.03-18.05-14.79-2.85-5.72-2.15
Shares Outstanding (Basic)
543111
Shares Outstanding (Diluted)
543111
Shares Change
26.28%39.15%121.72%0.39%2.08%-
EPS (Basic)
-3.57-4.28-4.86-2.10-4.20-1.62
EPS (Diluted)
-3.57-4.28-4.86-2.10-4.20-1.62
Free Cash Flow
-18.1-17.59-14.3-1.13-0.340.71
Free Cash Flow Per Share
-3.39-4.17-4.71-0.82-0.250.54
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-7711.98%-14686.17%-476.23%-403.52%-507.52%-52.52%
Profit Margin
-7304.73%-14625.85%-476.88%-407.73%-509.73%-53.27%
Free Cash Flow Margin
-6947.87%-14253.37%-461.11%-161.69%-30.13%17.69%
EBITDA
-18.85-18.05-14.77-2.82-5.7-2.12
EBITDA Margin
-7236.63%-14620.41%-476.23%-403.52%-507.52%-52.52%
Depreciation & Amortization
0.180.010000
EBIT
-19.03-18.05-14.77-2.82-5.7-2.12
EBIT Margin
-7304.73%-14625.85%-476.23%-403.52%-507.52%-52.52%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).